Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 5Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Peripheral Nervous System Diseases 1Colorectal Neoplasms 1Cognitive Dysfunction 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Silymarin × Clear all
NCT05631041 2023-12-22

Effect of Silymarin in Metastatic Colorectal Cancer Patients

Tanta University

Phase 3 Unknown
64 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Tanta University

Phase 2/3 Unknown
56 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡